Allergy/Immunology

Combining dupilumab with allergen immunotherapy shows promise for severe atopic dermatitis

Combining dupilumab, a biologic therapy, with subcutaneous immunotherapy (SCIT) shows promise as an effective and safe treatment for severe, treatment-refractory atopic dermatitis (AD), according to a study. The combination therapy significantly reduces disease severity, improves immune markers, and has a favorable safety profile, with only mild and temporary side effects...